KRAS and neoplasm: Here, through the use of various independent isogenic cellular models expressing near-endogenous levels of oncogenic or wild type (WT) KRAS, we demonstrate that oncogenic forms of KRAS render cells more resistant to ferroptosis through NRF2-mediated FSP1 upregulation in vitro and during tumor initiation in vivo.